BLUE
bluebird bio
BLUE
BLUE
Delisted
BLUE was delisted on the 30th of May, 2025.
175 hedge funds and large institutions have $309M invested in bluebird bio in 2023 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 67 increasing their positions, 41 reducing their positions, and 29 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less capital invested
Capital invested by funds: $ → $
7% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 29
1% less funds holding
Funds holding: 177 → 175 (-2)
32% less call options, than puts
Call options by funds: $3.89M | Put options by funds: $5.74M
Holders
175
Holding in Top 10
2
Calls
$3.89M
Puts
$5.74M
Top Buyers
| 1 | +$12.5M | |
| 2 | +$9.87M | |
| 3 | +$5.71M | |
| 4 |
Walleye Capital
New York
|
+$3.06M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$2.7M |
Top Sellers
| 1 | -$9.14M | |
| 2 | -$6.92M | |
| 3 | -$6.37M | |
| 4 |
Millennium Management
New York
|
-$5.15M |
| 5 |
State Street
Boston,
Massachusetts
|
-$5.15M |